Status:
UNKNOWN
Clinical Trial of Probiotic Supplementation in Psoriasis Vulgaris
Lead Sponsor:
Dr. Soetomo General Hospital
Collaborating Sponsors:
Universitas Airlangga
Conditions:
Psoriasis Vulgaris
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Psoriasis is a chronic inflammatory skin disease (chronic and recurrent) which is influenced by various factors, namely genetics, immunological processes, and environmental triggers such as infection,...
Detailed Description
Psoriasis is a chronic inflammatory skin disease (chronic and recurrent) which is influenced by various factors, namely genetics, immunological processes, and environmental triggers such as infection,...
Eligibility Criteria
Inclusion
- Patient Group
- Psoriasis vulgaris patients with or without treatment
- Mild to moderate degree
- Age 18-70 years old
- Willing to give informed consent
- Healthy Control Group
- Undiagnosed as Psoriasis
- Body mass index (BMI) is matched with the patient group
- Age 18-70 years old
- Willing to give Informed Consent
Exclusion
- Patient Group
Key Trial Info
Start Date :
February 7 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT05254249
Start Date
February 7 2022
End Date
October 1 2022
Last Update
February 24 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Universitas Airlangga
Surabaya, East Java, Indonesia